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Abstract: Although many therapies are used in the management of neuropathic pain (NeP) 
due to polyneuropathy (PN), few comparison studies exist. We performed a prospective, 
non-randomized, unblended, efficacy comparison of the serotonin-norepinephrine reuptake 
inhibitor venlafaxine, as either monotherapy or adjuvant therapy, with a first-line medication 
for NeP, gabapentin, in patients with PN-related NeP. VAS pain scores were assessed after 
3 and 6 months in intervention groups and in a cohort of patients receiving no pharmaco-
therapy. In a total of 223 patients, we analyzed pain quantity and quality (visual analogue scale 
[VAS] score, Brief Pain Inventory [BPI]), quality of life and health status measures [EuroQol 
5 Domains, EQ-5D], Medical Outcomes Sleep Study Scale [MOSSS], Hospital Anxiety and 
Depression Scale [HADS] and Short Form 36 Health Survey [SF-36]) after 6 months of therapy. 
  Significant improvements in VAS pain scores occurred for all treatment groups after 6 months. 
  Improvements in aspects of daily life and anxiety were identified in all treatment groups. Our 
data suggest that monotherapy or adjuvant therapy with venlafaxine is comparable to gabapentin 
for NeP management. We advocate for head-to-head, randomized, double-blinded studies of 
current NeP therapies.
Keywords: peripheral neuropathy, neuropathic pain, pharmacotherapy, venlafaxine, 
  gabapentin
Introduction
Chronic polyneuropathy (PN) is a common condition1 estimated to occur in about 2.4% 
of the population, increasing to 8% in the elderly.2 Etiologies of PN are numerous, 
including diabetes mellitus, vitamin B12 deficiency, alcohol, vasculitis and immune-
related diseases1 as well as idiopathic causes.3 Neuropathic pain (NeP), referring to 
pain of peripheral or central nervous system origin and characterized by continuous 
or paroxysmal dysesthesias, occurs in up to 50% of patients with PN.4,5 Patients with 
NeP often describe burning, shooting or stabbing electrical sensations; allodynia and 
hyperalgesia may also occur.1 Chronic NeP reduces quality of life in several domains, 
and concomitant mood and sleep disorders often co-occur.6–9
Diversity in the management of NeP related to variations in severity, concomitant 
syndromes, and patient diversity, make NeP particularly challenging to manage.10,11 
Further, side effects often limit the beneficial effects of NeP pharmacotherapy.12 Journal of Pain Research 2010:3 34
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Even with use of a first-line agent such as gabapentin for 
NeP,13 only 67% of treated patients are able to tolerate a 
maximal therapeutic dosage and most of these patients still 
tolerate dizziness and somnolence.5 Despite the presence of 
guidelines for multiple pharmacotherapies for NeP,13,14 there 
are very few head-to-head studies to guide the clinician in 
making therapeutic decisions.15
Gabapentin, a 3-alkylated analogue of γ-amino butyric 
acid, is a well established anticonvulsant in the management 
of NeP.16–18 Gabapentin’s predominant activity in the relief 
of NeP is the modulation of calcium channels through its 
binding to α2-δ-subunit of the calcium channel complex,12 
  reducing pre-synaptic release of neurotransmitters. 
  Gabapentin does not act upon serotonin or norephinephrine 
reuptake,19 so its mechanisms of action are distinctly differ-
ent from agents such as the serotonin-norepinephrine reup-
take inhibitors (SNRIs). In Canada, gabapentin is considered 
  first-line therapy for NeP management13 and therefore a 
reasonable comparator for other agents used for NeP.
Newer management options include venlafaxine, one 
of the first-used SNRIs.20–25 Beyond reuptake inhibition of 
  serotonin and norepinephrine, venlafaxine also possesses 
sodium channel blockade activity, as seen with tricyclic 
antidepressant (TCA) medications,24 weak dopamine 
  reuptake inhibitor activity, and mild NMDA antagonism 
activity.26 Although venlafaxine may be associated with rare 
cardiac arrhythmias, suggesting the need for ongoing cardiac 
monitoring,14 its side effect profile is still preferable to those 
associated with TCAs, first-line agents for management of 
NeP.13 It is hypothesized that beneficial effects of SNRIs in 
NeP are seen only at higher doses at which the metabolite 
R-O-desmethylvenlafaxine inhibits noradrenaline;27 
  therefore, it is believed that dosing of venlafaxine below 
150 mg daily is ineffective for NeP. Further research into 
the benefits of venlafaxine for management of NeP remains 
necessary.
Although some studies have identified potential benefits 
of venlafaxine and gabapentin combination therapy,26 there 
are no studies that have compared the two therapies head-
to-head. The aim of this study was to compare the relative 
efficacy of these two contrasting therapies in the management 
of NeP in a real-life clinical setting. A specific emphasis 
was placed on analyzing reductions in pain perception and 
changes to other pain-related symptom scales and quality 
of life indices. We hypothesized that the two treatments 
groups would have unique efficacies in the treatment of 
NeP and that both groups would fare better than a control 
(no treatment) group.
Materials and methods
Patient assessment
We prospectively evaluated patients with PN-related NeP 
in a tertiary care neuromuscular clinic in Calgary. While 
patients were identified prospectively, this investigation was 
not designed as a randomized study or a prospective cohort 
examination, but rather as a part of their regular clinical care. 
All patients enrolled within these clinics provide informed 
consent for ethically approved assessment of their clinical 
outcomes during all management, studies examining their 
general well being at regular follow-up visits, and completion 
of questionnaires conducted at these clinics (Centre for 
Advancement of Health, University of Calgary). There 
was no specific consent obtained for use of gabapentin or 
  venlafaxine – prescription of these therapies was considered 
a part of standard medical care. Patients with PN-associated 
NeP were asked, “Do you have pain or discomfort over your 
feet and legs on a near-daily basis for more than 6 months?” 
All patients who responded positively with a clinical picture 
consistent with PN and presence of peripheral neuropathy 
were deemed to have NeP as a complicating feature of their 
PN. The DN4 questionnaire (DN4 questionnaire), with good 
sensitivity (83%) and specificity (90%),11 was used to identify 
clinical likelihood of NeP presence – only those patients with 
a score of 4 were considered eligible.
Peripheral neuropathy severity was assessed using the 
Toronto Clinical neuropathy score (TCNS), which is based 
upon history and examination and emphasizes sensory deficits 
as compared to other measures of peripheral neuropathy sever-
ity.28,29 Initially developed for use as a simple screening tool 
for diabetic peripheral neuropathy, the TCNS is based upon 
history and examination and emphasizes sensory deficits as 
compared to other measurements of the severity of peripheral 
neuropathy. The TCNS is a validated method of evaluation for 
peripheral neuropathy, higher TCNS scores being positively 
associated with greater pathological abnormality of sural 
nerve fiber density.28 During the assessment of their peripheral 
neuropathy, the most likely etiology of the neuropathy was 
also determined based upon laboratory investigations and 
clinical information. These investigations included complete 
blood count, electrolytes, urea, creatinine, alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), gamma-
glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), 
albumin, total bilirubin, international normalized ratio (INR), 
thyroid-stimulating hormone, fasting glucose, hemoglobin 
A1c, cobalamin, erythrocyte sedimentation rate, antinuclear 
antibody, extracted nuclear antibody testing, serum protein Journal of Pain Research 2010:3 35
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electrophoresis, rheumatoid factor, vitamin B12 levels, fasting 
methylmalonic acid, and fasting homocysteine levels. Other 
testing was completed if a specific cause was suspected. 
All patients had electrophysiological testing as part of their 
regular care. In rare situations, a peripheral nerve biopsy 
was performed to supplement clinical diagnosis. There is no 
gold standard for the diagnosis of PN,30,31 so the final clinical 
diagnosis was based upon the judgment of the attending neu-
rologist. However, PN was defined to be present if a patient 
had a TCNS score of 3 including the mandatory presence 
of sensory abnormalities on distal bilateral leg examination 
unless another reason for the observed findings other than 
PN could be inferred. Thus, patients without evidence of 
physical examination signs of PN were excluded from further 
  assessment. Patients were excluded from further consideration 
if another condition other than PN such as a rheumatological 
disorder or peripheral vascular disease was present in the 
lower extremities. Peripheral vascular pulses were palpated 
in all cases, and if difficult to detect or absent, then patients 
were excluded due to possible confounding peripheral vas-
cular disease. Likewise, patients with symptoms of pain only 
present during exertion were excluded due to the possibility 
of confounding peripheral vascular disease.
Study design
Although these patients were identified in prospective 
manner, this study was designed to be a prospective cohort 
  investigation providing a study of best clinical care. No 
  randomization or blinding was performed. Patients were 
seen on three occasions during the study as part of standard 
care. During the first visit, determination of the cause of PN, 
  determination of the presence of NeP, and the decision to 
  initiate pharmacotherapy for NeP occurred. The decision 
to begin a specific pharmacotherapy was made by the patient 
after sufficient discussion of the agents and the possible antici-
pated adverse events in concert with the neurologist – attempts 
to emphasize the use of any one of the open-label medications 
were avoided. Attempted prior therapy for NeP in the past 
or present was permitted. Patients taking no medications for 
pain in the prior 30 days before assessment and initiating 
therapy were considered as receiving monotherapy. Patients 
taking other medications for pain relief at the time of initial 
visit were considered as receiving adjuvant therapy. Enroll-
ment was not permitted if patients discontinued or modified 
their medications used in the 30 days prior to study initiation; 
these patients were asked to return after 30 days from last 
pain medication modification occurred, at which time their 
previous medication use was considered stable. In addition to 
monitoring those patients receiving pharmacotherapy, patients 
were also monitored when no pharmacotherapy was desired 
or selected (control group).
Pharmacotherapy: venlafaxine  
or gabapentin monotherapy  
or adjuvant treatment
Following their assessment, patients were offered pharmaco-
therapy as part of their pain-management protocol. Careful 
recording of their current NeP medications prior to initiation 
of therapy were performed. Patients were initiated on ven-
lafaxine or gabapentin as monotherapy or adjuvant therapy. 
Flexible dosing was used for all patients, with varying 
initiation doses for venlafaxine and gabapentin; in all cases, 
however, medication doses were uptitrated slowly. In addi-
tion to monitoring those patients receiving pharmacotherapy, 
patients receiving no pharmacotherapy were also monitored 
(control group).
All patients were contacted via telephone 1 week after 
starting monotherapy or adjuvant therapy to assess for any 
adverse effects. Additional clinical follow-ups occurred at 
3- and 6-month intervals to perform studies related to the 
primary and secondary objectives, when adverse events 
were also recorded. If tolerating the medication well at the 
3 month follow-up point, patients were given the opportunity 
to modulate the dose either higher or lower for the remaining 
3 months. Patients with benefits but with tolerable adverse 
events were permitted to reduce the dose of the medication 
being used. We attempted to ensure that concomitant pain 
medications were not altered in the adjuvant therapy group. 
Patients were advised to contact the prescribing clinic for 
any possible adverse effects or clinical difficulties with pain 
during the time course of the study.
Primary outcome measure
Data for primary outcome measures were collected in groups 
of patients receiving interventions as well as in control group 
patients. At each visit the primary outcome measure; the 
degree of NeP (quantity and quality) was evaluated using a 
VAS provided by a line bisection score with an unmarked 
10 cm line between anchors of no pain on the left (0) and 
worst possible pain on the right (10). The marked score was 
asked to reflect the patient’s average PN-related NeP severity 
over the past 24 hours. The VAS was scored by line measure-
ment in each case. The last available data points were used 
for calculation of VAS in the case of drop out from the study. 
Data for pain quantity were collected at 0-, 3- and 6-month 
intervals for all patients.Journal of Pain Research 2010:3 36
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Secondary outcome measures
Data for secondary outcome measures were collected in 
groups of patients receiving interventions as well as in control 
group patients. Secondary outcomes consisted of health status 
and quality of life assessments. The Brief Pain Inventory 
(BPI), EuroQol 5 Domains (EQ-5D), Medical Outcomes 
Sleep Study Scale (MOSSS), Hospital Anxiety and Depres-
sion Scale (HADS) and Short Form 36 Health Survey (SF-36) 
were determined at study entry and after 6 months. The BPI 
provides information on the intensity of pain as well as the 
degree to which pain interferes with function, and enquires 
about pain relief, pain quality, and the patient’s perception 
of the cause of pain. The EQ-5D has two sections – the 
first section examines the health state in 5 dimensions: 
mobility, self-care, usual activities, pain/complaints, and 
anxiety/depression. We calculated EQ-5D utility scores and 
VAS scores as described previously.32,33 The MOSSS is a 
12-item self-report sleep measure, that can be used to assess 
important aspects of sleep perceived by adults.34 The HADS 
is another self-assessment scale that has been found to be a 
reliable instrument for detecting states of depression and 
anxiety in the setting of an outpatient clinic. Its subscales are 
also valid measures of severity of the emotional disorder.35 
The SF-36 Health Survey is a 36-item generic measure of 
health status.9
Medication adverse effects were documented during the 
telephone interview at one week after medication initiation, 
as well as at 3- and 6-month study visits.
To gauge global improvement, the Patient Global Impres-
sion of Change scale (PGIC) was administered at the 6-month 
endpoint visit. Both scales were analyzed using modified 
ridit transformation with the Cochran-Mantel-Haenszel 
procedure, with adjustment for center.
Tolerability and adverse events
An adverse event was defined as any noxious, unintended 
or unexpected response suspected to have a causal relation-
ship with the medication used. Identification of intolerable 
side effects at the time of follow-up visit or leading to 
discontinuation of medication prior to the follow-up visit 
was determined at the multiple follow-up points. A serious 
adverse event was defined as any life-threatening reaction 
to medication requiring hospitalization, additional urgent 
physician assessment, or resulted in persistent or significant 
disability. Patients were also asked to identify any tolerable 
side effects felt to be related to the medication. Side effects 
were accumulative throughout the study, such that a side 
effect experienced in the first 3 months but not the next 
3 months was still recorded as a side effect for both 3- and 
6-month follow-ups.
Data analysis
All patients enrolled in the NeP clinic provided informed 
consent to have their longitudinal data analyzed. All data 
were analyzed using unmatched ANOVA testing between 
intervention groups and between time points. Data were 
separated to analyze patients receiving monotherapy and 
adjuvant therapy. The baseline pain VAS score was used 
for comparison to later pain scores, and the 3-month pain 
VAS score was compared to the 6-month VAS pain score 
also. Changes in pain scores during the study period were 
  compared between treatment groups and the control cohort. 
An intention to treat analysis was performed once patients 
were seen for follow-up, with the last observations carried 
forward in the case of lost follow-up or discontinuation. 
The Cochran-Mantel-Haenszel procedure was used to 
  analyze PGIC data. Missing data were treated using the last 
  observation carried forward in all cases.
Results
A total of 95 NeP patients initiated monotherapy: 43 with 
venlafaxine and 52 with gabapentin. A total of 109 patients 
were already on NeP pharmacotherapy and initiated on adju-
vant therapy: 45 with venlafaxine and 64 with gabapentin. 
A cohort group of 29 patients with PN-related NeP did not 
receive pharmacological treatment and were monitored in 
an identical fashion for the 6-month follow-up period and 
considered a control group (Figure 1).
Patients in each treatment group and in the control group 
were similar with respect to age, sex, and severity of the 
neuropathy prior to the study initiation (Table 1). Control 
patients, however, had significantly lower VAS scores at 
baseline than each of the treatment groups. No significant 
difference in baseline VAS scores within treatment groups 
was present (ANOVA, P = 0.32 for monotherapy groups, 
P = 0.44 for adjuvant therapy groups).
After initial titration periods, venlafaxine and gabap-
entin dosing varied between individual patients (Table 2), 
but was slightly higher for each therapy in monotherapy 
treated patients as compared to adjuvant therapy patients 
(Tables 2, 3). In monotherapy patients, the mean dose of 
venlafaxine was just over 220 mg daily after 3 and 6 months. 
In patients receiving monotherapy gabapentin, the mean 
dose was just under 2400 mg daily after 3 and 6 months. In 
adjuvant therapy patients, the mean dose of venlafaxine was 
just under 220 mg daily after both 3 and 6 months. In patients Journal of Pain Research 2010:3 37
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receiving adjuvant gabapentin, the mean dose was just under 
1900 mg daily after 3 and 6 months (Tables 2, 3).
The control group data is presented in Table 4. Control 
group patients had less significant pain at baseline – this may 
have contributed to their selection not to receive pharmaco-
therapy. The control group also had better sleep and function-
ing parameter results than seen in the intervention groups.
Primary outcome measures
Monotherapy
For patients treated with venlafaxine or gabapentin as mono-
therapy, there was a significant improvement in VAS pain 
scores after 3 and 6 months of treatment compared to baseline 
VAS pain scores. There was also a significant improvement 
in scores at 6 months versus 3 months for both venlafaxine 
and gabapentin treatment groups (Table 2). Both treatment 
groups had greater relative improvement in VAS pain 
scores when compared to control patients at 3- and 6-month 
  follow-up visits.
Adjuvant therapy
VAS pain scores significantly improved for patients treated 
with venlafaxine adjuvant therapy at both 3 and 6 months 
compared to baseline VAS pain scores (Table 3). Venlafaxine 
adjuvant therapy was also associated with a significant 
improvement in VAS pain scores at 6-month visits versus 
3-month visits. All patients treated with adjuvant therapy 
had greater relative improvement in VAS scores compared 
to control patients over the same periods of time.
Secondary measures
Monotherapy
There were no significant improvements in EQ-5D scores, 
EQ-5D domains or EQ-Health status scores at 6-month 
visits versus baseline for any monotherapy treatment group 
(Table 2). Both gabapentin and venlafaxine monotherapy was 
associated with improvement in sleep disturbance and sleep 
adequacy within the MOSSS (Table 2). Venlafaxine mono-
therapy was further associated with additional improvements 
 PN patients with NeP 
screened
109 adjuvant therapy 
patients  
95 monotherapy 
patients  
43 patients 
starting
venlafaxine 
29 patients chose to
receive no therapy
52 patients 
starting
gabapentin
45 patients add
on venlafaxine
64 patients add
on gabapentin
 Patients
continuing
venlafaxine
monotherapy
33 patients
completed
venlafaxine
monotherapy
29 patients continuing to
receive no therapy
Six-month follow-up visit 
Three-month follow-up visit 
 Patients unable to participate
• Refused to complete
questionnaires
 
PN patients with NeP to 
have therapy initiated 
37 patients
continuing
gabapentin
monotherapy
33 patients
completed
gabapentin
monotherapy
40 patients
continuing
venlafaxine
adjuvant
therapy
36 patients
completed
venlafaxine
adjuvant
therapy
52 patients
continuing
gabapentin
adjuvant
therapy
46 patients
completed
gabapentin
adjuvant
therapy
29 patients continuing to
receive no therapy
Figure 1 Summary of patient flow throughout study.
Abbreviations: NeP, neuropathic pain; PN, polyneuropathy.Journal of Pain Research 2010:3 38
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Table 1 Clinical features and baseline characteristics of patients and control subjects studied
Clinical features Monotherapy Adjuvant therapy
Venlafaxine  
(n = 43)
Gabapentin  
(n = 52)
Venlafaxine  
(n = 45)
Gabapentin  
(n = 64)
Control group 
(no therapy) 
(n = 29)
Age (mean ± SD) 59 ± 7 61 ± 9 56 ± 5 61 ± 6 62 ± 9
Female sex (%) 27 (63%) 31 (60%) 28 (62%) 37 (58%) 17 (59%)
Age of onset of NeP  
symptoms (years),  
mean ± SD
57 ± 11 58 ± 13 55 ± 9 58 ± 15 59 ± 16
Age of initiation of  
NeP therapy  
initiation (years),  
mean ± SD
58 ± 10 59 ± 14 55 ± 9 60 ± 14 60 ± 15
Etiology of PN
Idiopathic 6 8 7 12 5
Diabetic 12 16 14 17 8
Vit B12 9 11 6 7 3
MGUS 4 2 2 5 3
Alcoholic 2 4 5 9 1
Immune 3 4 2 6 3
Hereditary 2 3 2 2 1
Other 5 4 7 6 5
TCSS 12.3 ± 4.3 12.0 ± 3.8 11.9 ± 4.2 13.2 ± 3.5 12.5 ± 4.0
Pre-existing NeP  
Therapies, number  
of patients using  
and average dose
N/A N/A Amitryptyline (n = 15),  
17.5 ± 12.5 mg/d  
Nortriptyline (n = 2),  
50 mg/d  
Carbamazepine (n = 2),  
300 ± 141 mg/d  
Valproic acid (n = 1)  
750 mg/d   
Phenytoin (n = 2),  
250 mg/d  
Nabilone (n = 3)  
1.50 ± 0.50 mg/d  
Morphine (n = 14)  
54 ± 27 mg/d  
Fentanyl (n = 1)  
50 µg/d  
Oxycodone (n = 7)  
33 ± 17 mg/d  
Acetaminophen (n = 4) 
722 ± 368 mg/d  
Codeine (n = 2)  
105 ± 86 mg/d
Amitryptyline (n = 22),  
18.3 ± 12.9 mg/d  
Nortriptyline (n = 2),  
25 ± 0 mg/d  
 
 
Carbamazepine  
(n = 5), 380 ± 148 mg/d  
 
 
 
Phenytoin (n = 2),  
250 ± 70 mg/d  
Venlafaxine (n = 3)  
150 mg/d  
Morphine (n = 20)  
48 ± 23 mg/d  
Fentanyl (n = 2)  
63 ± 18 µg/d  
Oxycodone (n = 13  
39 ± 18 mg/d  
Acetaminophen (n = 2)  
650 ± 168 mg/d  
Codeine (n = 4)  
141 ± 77 mg/d
N/A
Pre-existing side effects of NeP therapies
Sedation 14 (31%) 17 (26%)
Dizziness  
(lightheadedness)
10 (22%) 16 (25%)
Peripheral edema 1 (2%) 1 (2%)
Fatigue 14 (31%) 12 (19%)
(Continued )Journal of Pain Research 2010:3 39
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Table 1 (Continued)
Clinical features Monotherapy Adjuvant therapy
Venlafaxine  
(n = 43)
Gabapentin  
(n = 52)
Venlafaxine  
(n = 45)
Gabapentin  
(n = 64)
Control group 
(no therapy) 
(n = 29)
Dry mouth 5 (11%) 5 (8%)
Headache 6 (13%) 4 (6%)
Other 15 (33%) 20 (31%)
Total responses of  
adverse effects
65 75
Number of patients  
with adverse effects  
prior to initiation of  
studied therapies
20 (44%) 25 (39%)
Duration of time using  
NeP therapy prior to  
initiation of studied  
therapies (months)
11.9 ± 5.2 14.6 ± 6.1
Notes: Data are presented as mean ± standard deviation, or as an absolute number. ANOVA tests were performed to compare groups receiving monotherapy as well as the 
two groups receiving adjuvant therapy. *indicates a significant difference with ANOVA testing when the intervention group was compared to the control group.
Abbreviations: MGUS, monoclonal gammopathy of uncertain significance; NeP, neuropathic pain; PN, polyneuropathy; TCNS, Toronto Neuropathy Clinical Score.
in sleep quantity and in the sleep problems index (Table 2). 
Within the SF-36 domains, both venlafaxine and gabapentin 
monotherapy improved physical functioning, bodily pain, and 
vitality. Venlafaxine monotherapy further improved the SF-36 
domains of general health and mental health. Both gabapentin 
and venlafaxine monotherapy led to improvements in BPI 
subscales, including average pain, present pain; as well as with 
pain interference with general activity, walking ability, normal 
work, social relations, sleep, and enjoyment of life. Venlafax-
ine monotherapy additionally assisted with pain related inter-
ference with mood (Table 2). Monotherapy with venlafaxine 
improved the total HADS score as well as the HADS-A score 
(but not the HADS-D score). Monotherapy with gabapentin 
improved the HADS-A score only (Table 2).
Adjuvant therapy
There were no significant improvements in EQ-5D scores or 
EQ-Health status scores at 6 month visits versus baseline for 
any adjuvant therapy treatment group (Table 3). However, 
venlafaxine adjuvant therapy was associated with improved 
EQ-5D Self Care scoring at 6 months. Both gabapentin and 
venlafaxine adjuvant therapy was associated with improvement 
in sleep disturbance within the MOSSS (Table 3). Venlafax-
ine adjuvant therapy was further associated with additional 
improvements in sleep adequacy, sleep quantity and in the 
sleep problems index (Table 3). Within the SF-36 domains, 
both venlafaxine and gabapentin adjuvant therapy improved 
physical functioning and bodily pain. Venlafaxine adjuvant 
therapy further improved the SF-36 domain of mental health. 
Both gabapentin and venlafaxine adjuvant therapy improved 
BPI subscales including average pain and interference with 
mood and sleep. Venlafaxine adjuvant therapy additionally 
assisted with pain-related interference for walking ability and 
social relations, while gabapentin adjuvant therapy addition-
ally assisted with pain-related interference for general activity, 
normal work, and enjoyment of life (Table 3). Adjuvant therapy 
with venlafaxine improved the total HADS score as well as the 
HADS-A score (but not the HADS-D score); gabapentin adju-
vant therapy improved the HADS-A score only (Table 2).
Adverse events
All treatment groups suffered some attrition. Discontinuation 
rates ranged from 19% to 46% in each group, the greatest 
percentage of discontinuation being seen in the gabapentin 
monotherapy group. Discontinuations were related to devel-
opment of intolerable side effects as well as drug inefficacy. 
Although gabapentin therapy had a trend towards greater 
discontinuation of pharmacological therapy, there were no 
significant differences between intervention groups.
In the monotherapy groups, a total of 21 patients stopped 
treatment at or before the 3-month follow-up visit. The 
most common side effects for all patients receiving either 
monotherapy were sedation, dizziness/lightheadedness 
and fatigue. At the 6-month visits, an additional 8 patients 
discontinued their medication due to inefficacy rather than 
intolerable side effects.
In the adjuvant therapy groups, a total of 17 patients 
discontinued medication at 3-month follow-up visits, due 
to a combination of intolerable side effects and perceived 
inefficacy. Sedation was found to be the most common side Journal of Pain Research 2010:3 40
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. effect in both adjuvant treatment groups. An additional 
8 patients receiving adjuvant therapy discontinued treatment 
at or before the 6-month follow-up visit due to medication 
inefficacy. There were no serious adverse events occurring 
within any treatment group.
Patient assessment
Global improvement was evaluated with the PGIC. On both 
the clinician-rated and the patient-rated instruments, there 
were responses in favor of monotherapy with either ven-
lafaxine or gabapentin compared to the control group (no 
therapy), whereas the adjuvant therapies were associated with 
less beneficial but significant responses (Figure 2).
Control group (no therapy)
The control group was stable over time in their levels of 
pain, sleep parameters, mood and anxiety scale values and in 
quality and functioning of life parameters (Table 4). None of 
these patients started other forms of therapy over the 6-month 
assessment period.
Discussion
Although there are guidelines for the management of NeP, 
very few head-to-head comparisons of pharmacotherapies 
exist. The present study suggests that venlafaxine as mono-
therapy or adjuvant treatment for NeP has similar benefits 
on pain severity, sleep, anxiety/depression and functioning 
compared to gabapentin. Based on our open-label results, 
venlafaxine adjuvant or monotherapy should be considered 
in NeP patients. Modulation of multiple NeP pathogenic 
pathways (“rational polytherapy”) may be beneficial in 
numerous patients with NeP, as demonstrated by the effi-
cacy of adjuvant therapy with either therapy of interest in 
this study.
We decided to use gabapentin as a comparator given 
its widespread use, reasonable adverse event profile, 
therapeutic benefits at sub-maximal dosing (1800 mg/day), 
low cost and acceptance as beneficial NeP therapy.13,18,36 It 
was expected that all treatment groups would fare better 
than the untreated, or control, group. Although the control 
group had lower VAS pain scores that changed little over 
time, there were similar improvements for both therapy 
groups that were not witnessed in the control group. Both 
venlafaxine and gabapentin, with proven efficacy in the 
treatment of NeP,12,23,37 demonstrated improvement in VAS 
pain scores, but also were associated with some improve-
ments in sleep, pain-associated psychiatric difficulties, 
and functional abilities. Previous studies examining low 
dose venlafaxine asserted a number needed to treat (NNT) Journal of Pain Research 2010:3 43
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of 5.5 (3.4–13.5),22 while higher dosing of venlafaxine 
provides a NNT of 4.6 (2.9–10.6)22 – thus, venlafaxine is 
suggested to be provided at a minimum of 150 mg daily23 
in order to manage pain. In comparison, gabapentin for 
management of NeP due to a peripheral nervous system 
disease is associated with an NNT of 4.3 (2.8–8.6).12 
Therefore, the expected therapeutic benefit for both groups 
is similar. In our study, the two pharmacotherapies were 
quite comparable for most parameters, although venlafax-
ine had possibly better efficacy in management of anxiety/
depression and sleep dysfunction than gabapentin. Our 
results suggest that venlafaxine is also an effective medi-
cation in NeP therapy, with benefits that are comparable 
to those of gabapentin.
The most common adverse event with the use of either 
venlafaxine or gabapentin was sedation, although the 
numbers of adverse events did not differ between the two 
therapies assessed. Sedation, lightheadedness/dizziness 
and fatigue were the most common adverse events to lead 
to discontinuation of therapy in all intervention groups. 
Inefficacy also occurred in 13% to 16% of patients with 
either pharmacotherapy. Global benefit assessed with the 
PGIC found overall beneficial effects within any of the four 
intervention groups compared to that of the control group 
receiving no pharmacotherapy.
Another SNRI, duloxetine, also reduces pain in patients 
with major depressive disorder.38 Interestingly, a post-hoc 
analysis of two independent, randomized, controlled tri-
als in patients with major depressive disorder comparing 
duloxetine with placebo identified that approximately 50% 
of duloxetine’s total effect on overall pain was independent 
of responses in depression, suggesting an independent anal-
gesic effect of duloxetine which may contribute to efficacy 
in diabetic peripheral NeP20,21 and fibromyalgia.39–41 The 
reuptake inhibition of both serotonin and norepinephrine has 
remained the proposed mechanism by which SNRIs allevi-
ates pain and improves mood through increased availability 
of serotonin and norepinephrine, important neurotransmit-
ters in descending pain inhibitory pathways in the central 
nervous system.42
There are a number of limitations associated with our 
results. The greatest limitation was a lack of randomization 
and blinding. The flexible dosing and variability in over-
all dosing performed was analogous to everyday clinical 
therapy, but may certainly limit the direct comparison of 
the agents considered. Selection bias may have occurred 
based upon the physician and patient choosing the desired 
therapy – in particular, it is possible, but unintended, that Journal of Pain Research 2010:3 46
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patients with history of psychiatric illness may have been 
more likely to start on venlafaxine. Flexible dosing, although 
commonly used in routine management, may have contrib-
uted to variability in efficacy or adverse events. There is no 
optimal control group for comparison – we selected a cohort 
group who chose to receive no pharmacotherapy, but these 
patients may have expectations of no improvement over 
time, and had lower baseline VAS scores. It is extremely 
difficult to control for such variables without performing a 
randomized, double-blinded, controlled study, although the 
expense of such a study with an assumed very large sample 
size is likely prohibitive. Although all patients were encour-
aged to use conservative measure to assist with NeP relief, 
including aerobic forms of exercise, there was no means 
of controlling for non-pharmaceutical interventions, nor 
was there any means of controlling for patients who also 
used over-the-counter medications for pain relief. Patients 
referred to our tertiary care clinic may have not been repre-
sentative of the general population of patients with PN and 
PN-mediated NeP.
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Table 4 Parameters measured for the control groups at baseline, 3 and 6 months after initiation of treatment
Control group (n = 29)
Baseline 3 month 6 month
VAS 29.6 ± 12.1 30.3 ± 12.7 30.4 ± 1.5
Absolute and %  
Improvement in VAS since initiation
-0.7 ± 6.8 (-2.3%) -0.8 ± 7.2 (-2.7%)
EQ-5D Mobility Score 1.3 ± 0.8 1.3 ± 0.8
EQ-5D Self Care Score 1.2 ± 0.8 1.3 ± 0.7
EQ-5D Usual Activities Score 1.3 ± 1.0 1.3 ± 0.9
EQ-5D Pain/Discomfort Score 2.1 ± 0.9 2.1 ± 0.9
EQ-5D Anxiety/Depression Score 1.6 ± 0.9 1.6 ± 0.8
EQ-5D Index Score 0.68 ± 0.26 0.67 ± 0.28
EQ-5D VAS 69.8 ± 21.5 69.3 ± 21.2
MOSSS Domains
Sleep Disturbance 28.4 ± 21.2 28.8 ± 22.0
Somnolence 27.3 ± 21.5 28.4 ± 22.5
Sleep Adequacy 56.4 ± 27.2 55.8 ± 26.8
Snoring 13.7 ± 16.6 14.0 ± 14.6
Awaken Short of Breath or with Headache 12.4 ± 17.1 14.3 ± 19.2
Quantity of Sleep (hours) 7.2 ± 2.8 7.1 ± 2.9
Sleep Problems Index 23.6 ± 16.7 24.1 ± 18.2
HADS (total) 9.4 ± 10.2 9.2 ± 10.8
HADS-A 5.3 ± 11.6 5.1 ± 11.8
HADS-D 4.1 ± 11.9 4.1 ± 11.6
SF-36 Domains
Physical Functioning 48.9 ± 31.3 49.7 ± 32.0
Role Physical 36.5 ± 17.8 35.1 ± 16.5
Bodily Pain 40.2 ± 19.2 42.6 ± 15.2
General Health 59.7 ± 24.7 54.4 ± 23.8
Vitality 37.4 ± 23.5 39.0 ± 24.1
Social Functioning 51.2 ± 28.3 54.7 ± 26.2
Role Emotional 40.6 ± 29.9 41.1 ± 28.0
Mental Health 63.7 ± 27.1 62.5 ± 24.6
BPI – pain severity
Worst Pain 5.4 ± 3.5 5.7 ± 3.4
Average Pain 4.1 ± 3.3 4.2 ± 3.2
Least Pain 1.5 ± 2.9 1.6 ± 3.1
Pain Now 4.7 ± 3.2 4.5 ± 3.0
Mean Severity 3.9 ± 3.1 4.0 ± 3.2
BPI – pain related interference
General Activity 4.1 ± 3.1 4.0 ± 3.1
Mood 3.2 ± 3.2 3.4 ± 3.1
Walking Ability 3.5 ± 3.0 3.7 ± 2.8
Normal Work 3.0 ± 3.1 3.0 ± 3.0
Relations with Others 3.2 ± 2.7 3.0 ± 2.8
Sleep 2.6 ± 3.1 2.5 ± 3.0
Enjoyment of Life 4.1 ± 2.8 3.9 ± 2.7
Mean Interference 3.4 ± 3.0 3.4 ± 3.1
Notes: Data are presented as mean ± standard deviation. ANOVA tests were performed to compare groups receiving monotherapy at the same time points.
Abbreviations: BPI, Brief Pain Inventory; EQ-5D, EuroQol 5 Domains; HADS, Hospital Anxiety and Depression Scale; MOSSS, Medical Outcomes Sleep Study Scale; 
NeP, neuropathic pain; VAS, visual analogue scale.Journal of Pain Research 2010:3 48
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NeP is a significant debilitating sequelae of PN that 
  usually demands pharmacotheapy. We advocate for 
future randomized, blinded, head-to-head studies of 
  pharmacotherapies in the management of NeP. Future studies 
examining combination therapy using agents with distinct 
mechanisms of action, such as venlafaxine and gabapentin, 
will be of benefit to determine possible additive effects. Our 
results suggest that therapies for NeP modulate parameters 
of sleep and mood/anxiety, and enhance functional abilities 
in addition to modifying pain severity. We suggest that both 
venlafaxine and gabapentin are appropriate and comparable 
adjuvant therapies and monotherapies in the management 
of NeP.
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